A prostaglandin analogue (ONO-802) in treatment of missed abortion, intrauterine fetal death and hydatiform mole: a dose-finding trial.
Forty-eight patients affected with missed abortion, intrauterine fetal death and hydatiform mole were treated with vaginal suppositories containing 1 mg of 16,16-dimethyl-trans-delta 2-PGE1 methyl ester (ONO-802). The patients were divided into two treatment groups. The first, Group A, was given one vaginal suppository every 3 h to a maximum of five suppositories. The product of conception was expelled in 95.8% of patients. In Group B the maximum number of suppositories was reduced to three. The product of conception was expelled in 100% of cases and the average duration of treatment was similar to that for the first group. Although side-effects were mild in both groups, they were reduced in the patients of Group B.
D000019:Abortifacient Agents / Q000627:therapeutic use*; D000020:Abortifacient Agents, Nonsteroidal / Q000009:adverse effects / Q000627:therapeutic use*; D000030:Abortion, Missed / Q000188:drug therapy*; D000282:Administration, Intravaginal; D000328:Adult; D000527:Alprostadil / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D005260:Female; D005313:Fetal Death / Q000188:drug therapy*; D006801:Humans; D006828:Hydatidiform Mole / Q000188:drug therapy*; D008875:Middle Aged; D011247:Pregnancy; D011459:Prostaglandins E, Synthetic / Q000009:adverse effects / Q000627:therapeutic use*; D013488:Suppositories; D013997:Time Factors; D014594:Uterine Neoplasms / Q000188:drug therapy*
D000019:Abortifacient Agents; D000020:Abortifacient Agents, Nonsteroidal; D011459:Prostaglandins E, Synthetic; D013488:Suppositories; C021182:gemeprost; D000527:Alprostadil